FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers

STOCKHOLM, SWEDEN, — August 9, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the FDA (US Food and Drug Administration) held a meeting with the Medical Devices Advisory Committee on July 28th and 29th to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection.Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for more high quality research to validate these technologies. “The standards